Successful treatment of type I pityriasis rubra pilaris with ixekizumab

Heibel, Haley Danielle

doi:10.1016/j.jdcr.2018.05.006

Cited by 20 publications

(14 citation statements)

References 13 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We report a new case of a PRP refractory to conventional systemic treatment successfully treated with ixekizumab. [5][6][7] This reinforces the role of the IL-23/Th17 axis in the pathogenesis of PRP as demonstrated by the work of Feldmeyer et al 8 The results of a singlearm trial on 12 PRP patients, who were treated with ixekizumab have been recently published with positive outcomes. 9 Until larger, randomized, multicenter trials are available, we believe that these reports can be a valuable tool.…”

mentioning

confidence: 55%

Successful treatment of resistant pityriasis rubra pilaris with ixekizumab

Penalba-Torres

Pinilla-Martín

Aragón‐Miguel

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Pityriasis rubra pilaris (PRP) is a rare papulosquamous dermatosis of uncertain etiology. Of the six subtypes described, the most frequent form is adult type I, which typically involves erythroderma and islets of respected skin, follicular hyperkeratosis and orange palmoplantar keratoderma. This entity continues to be a therapeutic challenge, as F I G U R E 1 Pityriasis rubra pilaris before and after treatment with ixekizumab. A-C, Exfoliative erythroderma with intense desquamation and orange palmoplantar keratoderma. D-F, After 6 months of treatment with ixekizumab

show abstract

mentioning

confidence: 55%

Successful treatment of resistant pityriasis rubra pilaris with ixekizumab

Penalba-Torres

Pinilla-Martín

Aragón‐Miguel

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…3 IL inhibitors have been successfully used in other reported cases of PRP; however, tildrakizumab had not previously been reported in PRP. 2,[4][5][6][7] Whilst our case was under review, Licata et al 2021 reported the first successful treatment of PRP with an IL-23 only inhibitor, tildrakizumab. 8 Given the notorious resistance of PRP to traditional therapies, the use of biological agents is a welcome addition.…”

Section: Discussionmentioning

confidence: 88%

Successful treatment of pityriasis rubra pilaris with tildrakizumab

Zagarella

Jiang

2021

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…The pivotal role of the IL-23/Th17 axis in some PRP patients has been emphasized recently [6] and results of previous case reports on IL-17 antagonists and the IL-12/23-directed ustekinumab in the treatment of PRP are promising [4,[7][8][9]. To our knowledge, it remains unclear whether IL-17 or IL-23 is the key cytokine in PRP.…”

Section: Discussionmentioning

confidence: 99%